Skip to main content
SpringerLink
Log in

Clinical Pharmacokinetics and Pharmacodynamics of Insulin Lispro Mixtures

  • Review Articles
  • Drug Disposition
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Rapid-acting insulin analogues such as insulin lispro and insulin aspart produce a more physiological profile of insulin activity than does conventional regular human insulin because of their unique pharmacokinetics. These insulin analogues are absorbed rapidly from the subcutaneous injection site, resulting in a better matching of the appearance of insulin in the circulation with nutrient absorption from the intestine. In addition, they are shorter-acting than regular human insulin, thus decreasing the risk of late postprandial hypoglycaemia due to inappropriate hyperinsulinaemia. Because self-prepared mixtures of these rapid-acting insulin analogues with longer-acting insulins such as neutral protamine Hagedorn (NPH) insulin have been shown to be clinically useful, and because manufactured fixed-ratio mixtures of regular human insulin and NPH already represent a large proportion of insulin use, manufactured fixed-ratio mixtures of insulin lispro and a sustained-release insulin known as NPL have been developed (insulin lispro mixtures).

NPL is a protamine-based insulin lispro formulation with pharmacokinetics and glucodynamics comparable to those of human NPH insulin. NPL was developed for use within insulin lispro mixtures because an exchange between soluble insulin lispro and protamine-bound human insulin within human NPH precludes prolonged storage of mixtures of these insulins. An insulin lispro mixture consisting of 25% insulin lispro and 75% NPL is now commercially available. This preparation is intended primarily as an alternative to human insulin 30/70, which is commonly used within a twice-daily injection regimen. A mixture containing 50% insulin lispro and 50% NPL is also available.

The rapid activity of insulin lispro is maintained within insulin lispro mixtures, allowing injection just prior to a meal, a convenience that is not available with commercial mixtures of regular human insulin and human NPH insulin, which should be injected 30 to 45 minutes prior to meals. As with insulin lispro itself, the rapid action of insulin lispro within the insulin lispro mixtures also results in a smaller increase in blood glucose levels after meals than with comparable human insulin mixtures. In addition, data from two studies have shown that when Mix25 is injected prior to the evening meal the incidence of nocturnal hypoglycaemia is decreased in comparison with the same dose of human insulin 30/70. The combined rapid and prolonged insulin activity provided by insulin lispro mixtures has been defined both in healthy subjects without diabetes and in patients with diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Fig. 2
Table II
Fig. 3
Fig. 4
Table III
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

Notes

  1. Use of tradenames is for product identification only and does not imply endorsement.

References

  1. Brange J, Owens DR, Kang S, et al. Monomeric insulins and their experimental and clinical implications. Diabetes Care 1993; 13: 23–954

    Google Scholar 

  2. Pfeifer MA, Halter JB, Porte D Jr. Insulin secretion in diabetes mellitus. Am J Med 1981; 70(3): 579–88

    Article  PubMed  CAS  Google Scholar 

  3. Torlone E, Pampanelli S, Lalli C, et al. Effects of the short-acting insulin analog [Lys(B28), Pro(B29)] on postprandial blood glucose control in IDDM. Diabetes Care 1996; 19(9): 945–52

    Article  PubMed  CAS  Google Scholar 

  4. Dimitriadis GD, Gerich JE. Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care 1983; 6: 374–7

    Article  PubMed  CAS  Google Scholar 

  5. Brems DN, Alter LA, Beckage MJ, et al. Altering the association properties of insulin by amino acid replacement. Protein Eng 1992; 5(6): 527–33

    Article  PubMed  CAS  Google Scholar 

  6. Koivisto VA. The human insulin analogue insulin lispro. Ann Med 1998; 30(3): 260–6

    Article  PubMed  CAS  Google Scholar 

  7. Anderson JH Jr, Koivisto VA. Clinical studies on insulin lispro. Drugs Today 1998; 34 Suppl. C: 37–50

    CAS  Google Scholar 

  8. Bantle JP, Lonzette N, Frankamp LM. Effects of anatomical region used for insulin injections on glycemia in type I diabetes subjects. Diabetes Care 1993; 16: 1592–7

    Article  PubMed  CAS  Google Scholar 

  9. ter Braak EW, Woodworth JR, Bianchi R, et al. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. Diabetes Care 1996; 19: 1437–40

    Article  PubMed  Google Scholar 

  10. Kelley DB, editor-in-chief. Medical management of type 1 diabetes. 3rd ed. Alexandria (VA): American Diabetes Association; 1998: 55–116

  11. Edelman SV, Henry RR. Insulin therapy for normalizing glycosylated hemoglobin in type II diabetes: application, benefits, and risks. Diabetes Rev 1995; 3(2): 308–34

    Google Scholar 

  12. Corcoran JS, Yudkin JS. A comparison of premixed with patient-mixed insulins. Diabet Med 1986; 3(3): 246–9

    Article  PubMed  CAS  Google Scholar 

  13. Bell DS, Cutter GR, Lauritano AA. Efficacy of a premixed semisynthetic human insulin regimen. Clin Ther 1989; 11(6): 795–801

    PubMed  CAS  Google Scholar 

  14. Cucinotta D, Mannino D, Lasco A, et al. Premixed insulin at ratio 3/7 and regular + isophane insulins at mixing ratios from 2/8 to 4/6 achieve the same metabolic control. Diabete Metab 1991; 17: 49–54

    PubMed  CAS  Google Scholar 

  15. Aronoff S, Goldberg R, Kumar D. Use of a premixed insulin regimen (Novolin® 70/30) to replace self-mixed insulin regimens. Clin Ther 1994; 16(1): 41–9

    PubMed  CAS  Google Scholar 

  16. Vignati L, Anderson JH Jr, Iverson PW, et al. Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin-dependent diabetes mellitus. Clin Ther 1997; 19(6): 1408–21

    Article  PubMed  CAS  Google Scholar 

  17. Looney KS, De Felippis MR, Hofer JD, et al. The chemical stability of insulin lispro protamine suspension and insulin lispro mixtures [abstract 942]. Diabetologia 1998; 41 (1 Suppl. 1): A243

    Google Scholar 

  18. De Fronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214–23

    Google Scholar 

  19. Radziuk JR, Bradley B, Welsh L, et al. Neutral protamine lispro: activity profile of s.c. administration with and without admixture of soluble lispro [abstract 849]. Diabetologia 1996; 39 (1 Suppl. 1): A224

    Google Scholar 

  20. Heise T, Weyer C, Serwas A, et al. Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Care 1998; 21(5): 800–3

    Article  PubMed  CAS  Google Scholar 

  21. Rave K, Heinemann L, Puhl L, et al. Premixed formulations of insulin lispro: activity profiles in type 1 diabetic patients [letter]. Diabetes Care 1999; 22(5): 865–6

    Article  PubMed  CAS  Google Scholar 

  22. Koivisto VA, Tuominen JA, Ebeling P. Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients. Diabetes Care 1999; 22(3): 459–62

    Article  PubMed  CAS  Google Scholar 

  23. Malone JK, Arora V, Woodworth JR, et al. Improved postprandial glycemic control with Humalog® Mix75/25™ after a standard test meal in patients with type 2 diabetes mellitus. Clin Ther 2000; 22: 222–30

    Article  PubMed  CAS  Google Scholar 

  24. Malone J, Yang H, Woodworth JR, et al. Humalog® Mix25™ offers better and more consistent mealtime control in patients with type 1 and type 2 diabetes than human insulin 30/70. Diabetes Metab 2000; 26: 481–7

    PubMed  CAS  Google Scholar 

  25. Roach P, Trautmann M, Arora V, et al. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro Mix25 and insulin lispro Mix50. Clin Ther 1999; 21(3): 523–34

    Article  PubMed  CAS  Google Scholar 

  26. Roach P, Yue L, Arora V. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Diabetes Care 1999; 22: 1258–61

    Article  PubMed  CAS  Google Scholar 

  27. Brash PD, Shaw K, UK Humalog Mix25 Study Group. Reduced nocturnal hypoglycaemia with twice daily insulin lispro low mixture compared to human insulin 30/70 in patients with type 2 diabetes [abstract]. Diabet Med 2001; 18 (2 Suppl.): 15

    Google Scholar 

  28. Anderson JH Jr, Brunelle RL, Keohane P, et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med 1997; 157(11): 1249–55

    Article  PubMed  CAS  Google Scholar 

  29. Anderson JH Jr, Brunelle RL, Koivisto VA, et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients in insulin-analog treatment. Diabetes 1997; 46(2): 265–70

    Article  PubMed  CAS  Google Scholar 

  30. Heller SR, Amiel SA, Mansell P, et al. Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. Diabetes Care 1999; 22(11): 1607–11

    Article  PubMed  CAS  Google Scholar 

  31. American Diabetes Association. Insulin administration. Diabetes Care 2001; 24 Suppl. 1: S94–S7

    Article  Google Scholar 

  32. Pein M, Deibler J, Roach P, et al. Improved glucose control following administration of a 75% insulin lispro/25% NPL mixture in patients with type 1 diabetes [abstract P942]. Diabetes Res Clin Pract 2000; 50 (1 Suppl.): S220

    Article  Google Scholar 

  33. Weyer C, Heise T, Heinemann L. Insulin aspart in a 30/70 premixed formulation: pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care 1997; 20(10): 1612–4

    Article  PubMed  CAS  Google Scholar 

  34. Christiansen JS, Ejskjaer N, Rasmussen M, et al. Testing the concept of administering thrice daily premixed insulin aspart in type 2 diabetes [abstract P318]. Diabetes Res Clin Pract 2000; 50 (1 Suppl.): S67

    Article  Google Scholar 

Download references

Acknowledgements

This work was sponsored by Eli Lilly and Company.

Appreciation is expressed to Pam Erickson for editorial assistance with the manuscript.

Author information

Authors and Affiliations

  1. Department of Medicine, Indiana University School of Medicine, Emerson Hall 421, Indianapolis, Indiana, 46202, USA

    Paris Roach

  2. Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts, USA

    James R. Woodworth

Authors
  1. Paris Roach
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James R. Woodworth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paris Roach.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Roach, P., Woodworth, J.R. Clinical Pharmacokinetics and Pharmacodynamics of Insulin Lispro Mixtures. Clin Pharmacokinet 41, 1043–1057 (2002). https://doi.org/10.2165/00003088-200241130-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-200241130-00003

Keywords

Search

Navigation